146 related articles for article (PubMed ID: 10366735)
1. OHIO-1 beta-lactamase mutants: the Arg244Ser mutant and resistance to beta-lactams and beta-lactamase inhibitors.
Lin S; Thomas M; Mark S; Anderson V; Bonomo RA
Biochim Biophys Acta; 1999 Jun; 1432(1):125-36. PubMed ID: 10366735
[TBL] [Abstract][Full Text] [Related]
2. Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme.
Lin S; Thomas M; Shlaes DM; Rudin SD; Knox JR; Anderson V; Bonomo RA
Biochem J; 1998 Jul; 333 ( Pt 2)(Pt 2):395-400. PubMed ID: 9735103
[TBL] [Abstract][Full Text] [Related]
3. Overcoming resistance to beta-lactamase inhibitors: comparing sulbactam to novel inhibitors against clavulanate resistant SHV enzymes with substitutions at Ambler position 244.
Thomson JM; Distler AM; Bonomo RA
Biochemistry; 2007 Oct; 46(40):11361-8. PubMed ID: 17848099
[TBL] [Abstract][Full Text] [Related]
4. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
Bonomo RA; Rudin SA; Shlaes DM
FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
[TBL] [Abstract][Full Text] [Related]
5. beta-Lactamase mutations far from the active site influence inhibitor binding.
Bonomo RA; Dawes CG; Knox JR; Shlaes DM
Biochim Biophys Acta; 1995 Feb; 1247(1):121-5. PubMed ID: 7873581
[TBL] [Abstract][Full Text] [Related]
6. Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130.
Helfand MS; Bethel CR; Hujer AM; Hujer KM; Anderson VE; Bonomo RA
J Biol Chem; 2003 Dec; 278(52):52724-9. PubMed ID: 14534312
[TBL] [Abstract][Full Text] [Related]
7. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
Giakkoupi P; Tzelepi E; Legakis NJ; Tzouvelekis LS
J Antimicrob Chemother; 1999 Jan; 43(1):23-9. PubMed ID: 10381097
[TBL] [Abstract][Full Text] [Related]
8. Selection and characterization of beta-lactam-beta-lactamase inactivator-resistant mutants following PCR mutagenesis of the TEM-1 beta-lactamase gene.
Vakulenko SB; Geryk B; Kotra LP; Mobashery S; Lerner SA
Antimicrob Agents Chemother; 1998 Jul; 42(7):1542-8. PubMed ID: 9660980
[TBL] [Abstract][Full Text] [Related]
9. Probing active site chemistry in SHV beta-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance.
Thomson JM; Distler AM; Prati F; Bonomo RA
J Biol Chem; 2006 Sep; 281(36):26734-44. PubMed ID: 16803899
[TBL] [Abstract][Full Text] [Related]
10. Construction and characterization of an OHIO-1 beta-lactamase bearing Met69Ile and Gly238Ser mutations.
Bonomo RA; Knox JR; Rudin SD; Shlaes DM
Antimicrob Agents Chemother; 1997 Sep; 41(9):1940-3. PubMed ID: 9303389
[TBL] [Abstract][Full Text] [Related]
11. Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
Papp-Wallace KM; Taracila M; Hornick JM; Hujer AM; Hujer KM; Distler AM; Endimiani A; Bonomo RA
Antimicrob Agents Chemother; 2010 Jul; 54(7):2867-77. PubMed ID: 20421396
[TBL] [Abstract][Full Text] [Related]
12. The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276.
Drawz SM; Bethel CR; Hujer KM; Hurless KN; Distler AM; Caselli E; Prati F; Bonomo RA
Biochemistry; 2009 Jun; 48(21):4557-66. PubMed ID: 19351161
[TBL] [Abstract][Full Text] [Related]
13. Mutagenesis of amino acid residues in the SHV-1 beta-lactamase: the premier role of Gly238Ser in penicillin and cephalosporin resistance.
Hujer AM; Hujer KM; Bonomo RA
Biochim Biophys Acta; 2001 May; 1547(1):37-50. PubMed ID: 11343789
[TBL] [Abstract][Full Text] [Related]
14. Complementary roles of mutations at positions 69 and 242 in a class A beta-lactamase.
Bonomo RA; Dawes CG; Knox JR; Shlaes DM
Biochim Biophys Acta; 1995 Feb; 1247(1):113-20. PubMed ID: 7873579
[TBL] [Abstract][Full Text] [Related]
15. Substitution of Met-69 by Ala or Gly in TEM-1 beta-lactamase confer an increased susceptibility to clavulanic acid and other inhibitors.
Madec S; Blin C; Krishnamoorthy R; Picard B; Chaibi el B; Fouchereau-Péron M; Labia R
FEMS Microbiol Lett; 2002 May; 211(1):13-6. PubMed ID: 12052544
[TBL] [Abstract][Full Text] [Related]
16. Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.
Papp-Wallace KM; Winkler ML; Taracila MA; Bonomo RA
Antimicrob Agents Chemother; 2015 Jul; 59(7):3710-7. PubMed ID: 25666153
[TBL] [Abstract][Full Text] [Related]
17. Elucidating the role of Trp105 in the KPC-2 β-lactamase.
Papp-Wallace KM; Taracila M; Wallace CJ; Hujer KM; Bethel CR; Hornick JM; Bonomo RA
Protein Sci; 2010 Sep; 19(9):1714-27. PubMed ID: 20662006
[TBL] [Abstract][Full Text] [Related]
18. Construction and characterization of mutants of the TEM-1 beta-lactamase containing amino acid substitutions associated with both extended-spectrum resistance and resistance to beta-lactamase inhibitors.
Stapleton PD; Shannon KP; French GL
Antimicrob Agents Chemother; 1999 Aug; 43(8):1881-7. PubMed ID: 10428907
[TBL] [Abstract][Full Text] [Related]
19. OHIO-1 beta-lactamase mutants: Asp179Gly mutation confers resistance to ceftazidime.
Bonomo RA; Rudin SD; Shlaes DM
FEMS Microbiol Lett; 1997 Jul; 152(2):275-8. PubMed ID: 9231421
[TBL] [Abstract][Full Text] [Related]
20. Substitutions at position 105 in SHV family β-lactamases decrease catalytic efficiency and cause inhibitor resistance.
Li M; Conklin BC; Taracila MA; Hutton RA; Skalweit MJ
Antimicrob Agents Chemother; 2012 Nov; 56(11):5678-86. PubMed ID: 22908166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
